〔1〕 ZHANG S, SU J, LI X, et al. Chinese SLE Treatment and Research Group (CSTAR) Registry: V. Gender Impact on Chinese Patients with Systemic Lupus Erythematosus〔J〕. Lupus, 2015, 24(12): 1267-1275.
〔2〕 TEKTONIDOU M G, LEWANDOWSKI L B, HU J X, et al. Survival in Adults and Children with Systemic Lupus Erythematosus: A Systematic Review and Bayesian Meta-Analysis of Studies from 1950 to 2016〔J〕. Ann Rheum Dis, 2017, 76(12): 2009-2016.
〔3〕 PAN Q J, CHEN J X, GUO L J, et al. Mechanistic Insights into Environmental and Genetic Risk Factors for Systemic Lupus Erythematosus〔J〕. Am J Transl Res, 2019, 11(3): 1241-1254.
〔4〕 WANG J M, XU W D, HUANG A F. Association of STAT4 Gene Rs7574865, Rs10168266 Polymorphisms and Systemic Lupus Erythematosus Susceptibility:A Meta-Analysis〔J〕. Immunol Investig,2021,50(2/3):282-294.
〔5〕 SANDLING J K, PUCHOLT P, ROSENBERG L H, et al. Molecular Pathways in Patients with Systemic Lupus Erythematosus Revealed by Gene-Centred DNA Sequen-cing〔J〕. Ann Rheum Dis, 2021, 80(1): 109-117.
〔6〕 LEEK J T, STOREY J D. Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis〔J〕. PLoS Genet, 2007, 3(9): 1724-1735.
〔7〕 RITCHIE M E, PHIPSON B, WU D, et al. Limma Powers Differential Expression Analyses for RNA-Sequencing and Microarray Studies〔J〕. Nucleic Acids Res,2015,43(7): e47.
〔8〕 ZHANG B, HORVATH S. A General Framework for Weighted Gene Co-Expression Network Analysis〔J〕. Stat Appl Genet Mol Biol, 2005, 4: Article17.
〔9〕 SATO V A H, MARQUES I D B, GOLDENSTEIN P T, et al. Lupus Nephritis Is more Severe in Children and Adolescents than in Older Adults〔J〕. Lupus, 2012, 21(9): 978-983.
〔10〕 ALVES P, BANDARIA J, LEAVY M B, et al. Validation of a Machine Learning Approach to Estimate Systemic Lupus Erythematosus Disease Activity Index Score Categories and Application in a Real-World Dataset〔J〕. RMD Open, 2021, 7(2): e001586.
〔11〕 DEVILLIERS H, AMOURA Z, BESANCENOT J F, et al. LupusQoL-FR Is Valid to Assess Quality of Life in Patients with Systemic Lupus Erythematosus〔J〕. Rheu-matology (Oxford), 2012, 51(10): 1906-1915.
〔12〕 HILLMER E J, ZHANG H Y, LI H S, et al. STAT3 Signaling in Immunity〔J〕. Cytokine Growth Factor Rev, 2016, 31: 1-15.
〔13〕 RAPHAEL I, NALAWADE S, EAGAR T N, et al. T Cell Subsets and Their Signature Cytokines in Auto-immune and Inflammatory Diseases〔J〕. Cytokine, 2015, 74(1): 5-17.
〔14〕 YANG X O, PANOPOULOS A D, NURIEVA R, et al. STAT3 Regulates Cytokine-Mediated Generation of Inflammatory Helper T Cells〔J〕. J Biol Chem,2007,282(13): 9358-9363.
〔15〕 CHEN S Y, LIU M F, KUO P Y, et al. Upregulated Expression of STAT3/IL-17 in Patients with Systemic Lupus Erythematosus〔J〕. Clin Rheumatol,2019,38(5): 1361-1366.
〔16〕 ELLOUMI N, TAHRI S, FAKHFAKH R, et al. Role of Innate Immune Receptors TLR4 and TLR2 Polymorphisms in Systemic Lupus Erythematosus Susceptibility〔J〕. Ann Hum Genet, 2022, 86(3): 137-144.
〔17〕 LIU M H, ZEN K. Toll-Like Receptors Regulate the Development and Progression of Renal Diseases〔J〕. Kidney Dis (Basel), 2021, 7(1): 14-23.
〔18〕 GAY N J, SYMMONS M F, GANGLOFF M, et al. Assembly and Localization of Toll-Like Receptor Signal-ling Complexes〔J〕. Nat Rev Immunol, 2014, 14(8): 546-558.
〔19〕 PATRA M C, ACHEK A, KIM G Y, et al. A Novel Small-Molecule Inhibitor of Endosomal TLRS Reduces Inflammation and Alleviates Autoimmune Disease Symptoms in Murine Models〔J〕. Cells,2020,9(7):1648.
〔20〕 LU J C, YUE Y, XIONG S D. Extracellular HMGB1 Augments Macrophage Inflammation by Facilitating the Endosomal Accumulation of ALD-DNA via TLR2/4-Mediated Endocytosis〔J〕. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(10): 166184.
〔21〕 MA K Y, LI J Y, WANG X H, et al. TLR4+ CXCR4+ Plasma Cells Drive Nephritis Development in Systemic Lupus Erythematosus〔J〕. Ann Rheum Dis,2018,77(10):
1498-1506.
〔22〕 BAEK W Y, CHOI Y S, LEE S W, et al. Toll-Like Receptor Signaling Inhibitory Peptide Improves Inflammation in Animal Model and Human Systemic Lupus Erythematosus〔J〕. Int J Mol Sci,2021,22(23): 12764.
〔23〕 HUBBARD E L, GRAMMER A C, LIPSKY P E. Trans-criptomics Data: Pointing the Way to Subclassification and Personalized Medicine in Systemic Lupus Erythematosus〔J〕. Curr Opin Rheumatol,2021,33(6):579-585.
〔24〕 XING H P, PANG H Y, DU T, et al. Establishing a Risk Prediction Model for Atherosclerosis in Systemic Lupus Erythematosus〔J〕. Front Immunol,2021,12: 622216.
|